文献速递心外重症与机械循环支持

LATERAL临床试验:侧开胸植入离心流左心室辅助装置的评估

Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial.
PubMed 文献 · J Heart Lung Transplant · 2019-01-01

LATERAL试验为多中心前瞻性非随机单臂研究,利用144例INTERMACS数据库患者评估侧开胸植入HVAD的安全性及有效性。180天主要复合终点成功率达88.1%,显著高于预设绩效目标77.5%(p=0.0012);初始住院平均18天,显著短于预设目标26.1天(p<0.0001)。结论认为侧开胸植入HVAD是特定桥接移植患者中安全有效的替代方案。

要点

  • 侧开胸植入HVAD的180天复合终点成功率为88.1%,优于 sternotomy 历史数据设定的77.5%目标。
  • 初始住院平均18天,显著短于 sternotomy 历史数据设定的26.1天目标(p<0.0001)。
  • 侧开胸入路需再次手术的出血发生率显著低于既往 sternotomy 入路研究。

核心结论

  • 侧开胸植入HVAD在特定桥接移植患者中是安全有效的,可作为正中开胸的替代方案。

研究设计与样本

  • LATERAL试验为多中心、前瞻性、非随机、单臂研究,利用美国及加拿大26个中心INTERMACS数据库中144例患者数据。

主要发现

  • 180天主要复合终点成功率为88.1%,显著高于预设绩效目标77.5%(p=0.0012)。
  • 初始住院平均天数为18天,显著短于预设绩效目标26.1天(p<0.0001)。
  • 不良事件谱进一步证明侧开胸入路的安全性,总体生存良好。
  • 需再次手术的出血发生率显著低于既往 sternotomy 入路研究。

关键数值与推荐

  • 主要复合终点为180天时存活于原植入装置且无致残性卒中(改良Rankin量表评分>3)、未移植或未因恢复而取出装置。
  • 关键次要终点为初始住院平均天数。

临床怎么用

  • 在拟行桥接移植的特定患者中,可考虑采用侧开胸入路植入HVAD以缩短住院时间并降低出血再手术风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HeartWare centrifugal-flow ventricular assist device system (HVAD) is a viable option for treatment of advanced heart failure. There is a growing trend toward the use of less invasive techniques in cardiac surgery, and the thoracotomy technique for HVAD implantation may provide benefits not available with conventional approaches. METHODS: The LATERAL trial is a multicenter, prospective, non-randomized, single-arm trial that utilized data from 144 patients enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database at 26 centers in the United States and Canada. The primary composite end-point was success at 180 days defined as alive on the originally implanted device and free from disabling stroke (modified Rankin Scale score >3), transplanted or explanted for recovery. The key secondary end-point was mean length of initial hospital stay. RESULTS: The primary end-point was successfully achieved in 88.1% of patients and was significantly greater than the pre-defined performance goal of 77.5% set from historical sternotomy data (p = 0.0012). The key secondary end-point-mean length of initial hospital stay -was 18 days and was significantly shorter than the pre-defined performance goal of 26.1 days obtained from historical sternotomy data (p < 0.0001). The adverse event profile further demonstrated the safety of the thoracotomy approach. The overall patient survival was good, and bleeding requiring reoperation was significantly less frequent than that observed in previous studies using the sternotomy approach. CONCLUSIONS: This prospective clinical trial provides validation that implantation of the HVAD system via the thoracotomy approach used in the LATERAL study represents a safe and effective alternative to median sternotomy in selected patients intended for a bridge-to-transplant indication.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. McGee E, Danter M, Strueber M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. J Heart Lung Transplant. 2019. PMID: 30945636. doi:10.1016/j.healun.2019.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。